Cancer detection company extends global reach

    Nov. 15, 2006
    Zila adds Pacific Rim to ViziLite market.

    PHOENIX-- Zila, Inc. has acquired the rights to manufacture and distribute ViziLite in the Pacific Rim from President Medical Technologies, Inc., a Taiwanese company.

    This transaction completes the evolution of Zila from a licensee of the ViziLite technology, to owner of all ViziLite rights, including the underlying patented technology and world-wide distribution.

    Zila is executing its plan to establish ViziLite Plus as the new standard of care in oral cancer detection. ViziLite Plus is the most advanced technology on the market for the early detection of oral abnormalities that could lead to cancer.

    Zila's next generation oral cancer diagnostic product, OraTest, is currently proceeding through a Phase III clinical trial.

    "Oral cancer is a prevalent and deadly disease within the Pacific Rim. This transaction paves the way for strategic alliances for the distribution of our cancer detection products within the Pacific Rim. It is our goal to establish ViziLite Plus as the standard of care, not only in dental offices across the United States, but ultimately around the world," stated Zila Chairman, CEO and President, Douglas Burkett, Ph.D.

    In a separate release, Zila announced plans to acquire Professional Dental Technologies in order to strengthen the Company's ability to market and sell its oral cancer detection products in the United States.